^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SHR-4602
i
Other names: SHR-4602, SHR4602, SHR 4602
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
Microtubule inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
3ms
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Atridia Pty Ltd.
New P1 trial • Metastases
|
SHR-4602
4ms
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
P2, N=240, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Metastases
|
SHR-4602
over1year
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=133, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation • HER-2 expression
|
SHR-4602
over1year
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=133, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 mutation • HER-2 expression
|
SHR-4602
Share via
